A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
Walker A, Watson C, Alexopoulos ST, Deniz B, Arnold R, Bates D
Curr Med Res Opin. 2013 Dec 5. PMID: 24289170.Abstract